taizhou bolonpharmchem - China

Welcome to

taizhou bolonpharmchem

Free Member

taizhou bolonpharmchem
China

Home
Company Info
Contact Us
Share your thoughts
Language
- English

Company Profile

Company Contact

Name:

Ms. amanda

E-mail:

Send Message

Phone Number:

Address:

taizhou, Zhejiang
China

Average User Review

There is no review for this company - Write a review

Registration Date:

Jun. 25, 2024

Last Updated:

Jan. 1, 2014

Business Nature:

Manufacturing of Chemicals category

Want to contact this company?

Send Message

Your inquiry will be recorded in "Member Trade Mail".

Put on Company Partner

Recommend to your friends

Company Brief

Located in Taizhou, which is boasted for the State API Production Base in China, Bolon Pharmachem is a API and intermediate manufacturer dedicated in the area of oncology API and peptide API. Under the leadership of the core R& D members, who are sophisticated in oncology API development as PhD in Chinese Academy of Sciences as well as Canadian returned PhD who is exceptional at peptide synthesis, together with local professional who enjoy fruitful experience in penem series production, we believe our partner will enjoy the cooperation with us a R& D oriented company. Moreover, our main products including Glatiramer acetate Pepper Rings downstream products, Cabazitaxel, Fulvestrant , Thiophene Series etc. some will get GMP soon

In addition, in consideration of further development, we set up dedicated laboratory which is designed for the production part of oncology API. For all API production, we strictly follow up GMP rules, very strictly to high quality, many of API even better than EP, BP, and USP , also have good control on solvents and other spec like endotoxin, microbiology .

With the trend of Pharmaceutical production transfer from EU, USA to India and China, at the very begginning of Bolon Pharmachem, we decided to focus both on API production as well as contract manufacturing business.

I am familiar with this company and want to review it.

You have [3] new inquiries.